Abstract:OBJECTIVE To study the effect and the underlying molecular mechanisms of a novel histone deacetylases(HDAC) inhibitor named DWP0016 in lung carcinoma A549 cells and xenografts.METHODS ① In vitro: A549 cells were treated with DWP0016 0.625-10 μmol·L-1 for 48 h before cell viability was detected by MTT assay.The effect of DWP0016 on mRNA level of phosphatase and tensin homolog deleted on chromosome 10(PTEN) was detected by real-time PCR.The protein expression of total H3,acetylated-H3(Ac-H3),p21,PTEN,total-Akt and phosphorylated-Akt(p-Akt) was detected by Western blotting.② In vivo: Lewis lung cancer animal models were constructed by injecting the axillae with 0.2 ml tumor suspension.After 7 d,the xenografts groups were ip given DWP0016 12.5,25 and 50 mg·kg-1 and positive drug vorinostat(SAHA) 50 mg·kg-1,once daily,for 8 d.After treatment,the animals were sacrificed to get the tumors.The tumor specimens were weighed and the tumor growth inhibition was calculated.The expression of Ac-H3 and PTEN in the specimen was detected by immunohistochemical assay.RESULTS ① In vitro: MTT results showed that IC50 of DWP0016 was 2.51 μmol·L-1 and IC50 of SAHA was 6.03 μmol·L-1.Compared with normal control,DWP0016 significantly up-regulated the protein expression of Ac-H3 and p21 at the concentration of 2.5 μmol·L-1(P< 0.05).DWP0016 promoted the mRNA level and protein expression of PTEN while decreasing the expression of p-Akt concentration-dependently(P<0.05).② In vivo: compared with model group,the mean mass of the specimens from DWP0016 12.5 mg·kg-1 significantly decreased(P<0.05) with a 42.0% tumor growth inhibition.The tumor growth inhibition in DWP0016 50 mg·kg-1 group was higher than in SAHA 50 mg·kg-1 group(P<0.05).Compared with the model group,the expression of Ac-H3 and PTEN in tumor specimens was up-regulated by DWP0016.CONCLUSION DWP0016 effectively inhibits the proliferation in A549 cells and the tumor growth in xenografts.The molecular mechanisms are associated with the induction of Ac-H3,the activation of p21,PTEN and down-regulation of p-Akt.DWP0016 is a potent compound to be developed as an anti-tumor agent for clinic application in the future.

Inhibition of HDACs-EphA2 Signaling Axis with WW437 Demonstrates Promising Preclinical Antitumor Activity in Breast Cancer.

Inhibition of Breast Cancer Progression by a Novel Histone Deacetylase Inhibitor, LW479, by Down‐regulating EGFR Expression

Small molecule HDAC inhibitors: Promising agents for breast cancer treatment

A Novel Class I HDAC Inhibitor, AW01178, Inhibits Epithelial-Mesenchymal Transition and Metastasis of Breast Cancer

Antitumor Action of a Novel Histone Deacetylase Inhibitor, YF479, in Breast Cancer

Natural Derivatives of Selective HDAC8 Inhibitors with Potent in Vivo Antitumor Efficacy Against Breast Cancer

The histone deacetylase inhibitor PCI-24781 impairs calcium influx and inhibits proliferation and metastasis in breast cancer

Discovery of a Novel HDACi Structure That Inhibits the Proliferation of Ovarian Cancer Cells in Vivo and in Vitro

Discovery of the First-in-Class Dual-Target ROCK/HDAC Inhibitor with Potent Antitumor Efficacy in Vivo That Trigger Antitumor Immunity

Antitumor effects of a novel histone deacetylase inhibitor NK-HDAC-1 on breast cancer.

Dual targeting of retinoid X receptor and histone deacetylase with DW22 as a novel antitumor approach.

YF343, a Novel Histone Deacetylase Inhibitor, Combined with CQ to Inhibit- Autophagy, Contributes to Increased Apoptosis in Triple-Negative Breast Cancer

Design, Synthesis, and Biological Evaluation of Novel HDAC/CD13 Dual Inhibitors for the Treatment of Cancer.

Alteration of MDM2 by the Small Molecule YF438 Exerts Antitumor Effects in Triple-Negative Breast Cancer

Discovery of N-hydroxy-4-(3-phenylpropanamido)benzamide derivative 5j, a novel histone deacetylase inhibitor, as a potential therapeutic agent for human breast cancer.

Design, Synthesis and Biological Evaluation of HDAC and VEGFR Dual Inhibitors as a Multi-targeted Anticancer Agents

Discovering novel derivatives of STAT3 and HDAC inhibitors with anti-tumor activity

Inhibition of histone deacetylases attenuates tumor progression and improves immunotherapy in breast cancer

Potential of Dietary HDAC2i in Breast Cancer Patients Receiving PD-1/PD-L1 Inhibitors

Antitumor activity of histone deacetylases inhibitor,DWP0016,in lung carcinoma A549 cells and xenograft mouse model

Enhancing anti-cancer capacity: Novel class I/II HDAC inhibitors modulate EMT, cell cycle, and apoptosis pathways